OX40 Ligand Levels and High-Sensitivity C-Reactive Protein Levels in Blood from Local Coronary Plaque and the Femoral Artery in Patients with Acute Coronary Syndrome or Stable Angina
Free accessResearch articleFirst published online August, 2011
OX40 Ligand Levels and High-Sensitivity C-Reactive Protein Levels in Blood from Local Coronary Plaque and the Femoral Artery in Patients with Acute Coronary Syndrome or Stable Angina
OX40 ligand (OX40L) and high-sensitivity C-reactive protein (hs-CRP) play important roles in the pathogenesis of atherosclerosis. In this study, consecutive patients with acute coronary syndrome (ACS; n = 90) or stable angina (SA; n = 40) and healthy control subjects (n = 50) were evaluated to assess plasma OX40L and serum hs-CRP levels in local coronary plaque and the femoral artery. OX40L and hs-CRP levels in the femoral artery were significantly higher in patients with ACS compared with controls. OX40L and hs-CRP levels in local coronary plaque (OX40Lc and hs-CRPc, respectively) were significantly higher in ACS than in SA patients. OX40L and hs-CRP levels were positively correlated with each other and were also correlated with fibrinogen levels. The number of complex lesions was correlated with OX40Lc and hs-CRPc levels. It is concluded that the OX40Lc level was highly sensitive for evaluating the inflammatory response in ACS and elevated levels of OX40Lc may be a valuable predictive marker for increased risk of atherosclerotic progression in ACS patients.
LibbyPRidkerPMMaseriA: Inflammation and atherosclerosis. Circulation2002; 105: 1135–1143.
2.
HanssonGKLibbyP: The immune response in atherosclerosis: A double-edged sword. Nat Rev Immunol2006; 6: 508–519.
3.
TedguiAMallatZ: Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev2006; 86: 515–581.
4.
KatritsisDKorovesisSGiazitzoglouE: C-Reactive protein concentrations and angiographic characteristics of coronary lesions. Clin Chem2001; 47: 882–886.
5.
SalehNTornvallP: Serum C-reactive protein response to percutaneous coronary intervention in patients with unstable or stable angina pectoris is associated with the risk of clinical restenosis. Atherosclerosis2007; 195: 374–378.
6.
MuhlesteinJBHorneBDCarlquistJF: Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation2000; 102: 1917–1923.
7.
FigaroMKKritchevskySBResnickHE: Diabetes, inflammation, and functional decline in older adults: findings from the Health, Aging and Body Composition (ABC) study. Diabetes Care2006; 29: 2039–2045.
8.
WangXRiaMKelmensonPM: Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat Genet2005; 37: 365–372.
9.
HigginsLMMcDonaldSAWhittleN: Regulation of T cell activation in vitro and in vivo by targeting the OX40–OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J Immunol1999; 162: 486–493.
10.
CarboniSAboul-EneinFWaltzingerC: CD134 plays a crucial role in the pathogenesis of EAE and is upregulated in the CNS of patients with multiple sclerosis. J Neuroimmunol2003; 145: 1–11.
11.
NoharaCAkibaHNakajimaA: Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: A critical role for OX40 ligand in migration, but not development, of pathogenic T cells. J Immunol2001; 166: 2108–2115.
12.
van WanrooijEJvan PuijveldeGHde VosP: Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol2007; 27: 204–210.
13.
LiuDMYanJCWangCP: The clinical implications of increased OX40 ligand expression in patients with acute coronary syndrome. Clin Chim Acta2008; 397: 22–26.
14.
LedueTBWeinerDLSipeJD: Analytical evaluation of particle-enhanced immuno-nephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem1998; 35: 745–753.
15.
National Committee for Clinical Laboratory Standards (NCCLS): Procedure for the Determination of Fibrinogen in Plasma, Approved Guideline H30-A. NCCLS: Wayne, PA, 1999: p 99.
16.
GensiniGG: A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol1983; 51: 606.
17.
PatersonDJJefferiesWAGreenJR: Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol Immunol1987; 24: 1281–1290.
18.
GodfreyWRFagnoniFFHararaMA: Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. J Exp Med1994; 180: 757–762.
19.
SugamuraKIshiiNWeinbergAD: Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol2004; 4: 420–431.
20.
NorjaSNuutilaLKarhunenPJ: C-reactive protein in vulnerable coronary plaques. J Clin Pathol2007; 60: 545–548.
21.
DanenbergHDSzalaiAJSwaminathanRV: Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation2003; 108: 512–515.
22.
PasceriVWillersonJTYehET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation2000; 102: 2165–2168.
23.
TorzewskiMRistCMortensenRF: C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol2000; 20: 2094–2099.
24.
HaverkateFThompsonSGPykeSD: Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet1997; 349: 462–466.
25.
GreenDFoilesNChanC: Elevated fibrinogen levels and subsequent subclinical atherosclerosis: the CARDIA Study. Atherosclerosis2009; 202: 623–631.
26.
Viles-GonzalezJFFusterVBadimonJJ: Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences. Eur Heart J2004; 25: 1197–1207.
